A2LC34 Stock Overview
Researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Alcon Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF47.84 |
| 52 Week High | CHF48.94 |
| 52 Week Low | CHF35.72 |
| Beta | 0.70 |
| 11 Month Change | 14.48% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 18.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| A2LC34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | -1.8% | -0.4% | 0.7% |
| 1Y | n/a | -0.4% | -4.4% |
Return vs Industry: Insufficient data to determine how A2LC34 performed against the BR Medical Equipment industry.
Return vs Market: Insufficient data to determine how A2LC34 performed against the BR Market.
Price Volatility
| A2LC34 volatility | |
|---|---|
| A2LC34 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.0% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 9.2% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: A2LC34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A2LC34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1945 | 25,000 | David Endicott | www.alcon.com |
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company’s Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery.
Alcon Inc. Fundamentals Summary
| A2LC34 fundamental statistics | |
|---|---|
| Market cap | R$238.90b |
| Earnings (TTM) | R$5.70b |
| Revenue (TTM) | R$52.03b |
41.9x
P/E Ratio4.6x
P/S RatioIs A2LC34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A2LC34 income statement (TTM) | |
|---|---|
| Revenue | US$9.56b |
| Cost of Revenue | US$4.24b |
| Gross Profit | US$5.32b |
| Other Expenses | US$4.28b |
| Earnings | US$1.05b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 21, 2024
| Earnings per share (EPS) | 2.12 |
| Gross Margin | 55.67% |
| Net Profit Margin | 10.96% |
| Debt/Equity Ratio | 22.5% |
How did A2LC34 perform over the long term?
See historical performance and comparison